The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome
Open accessAbstract
Deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT) activity is an inborn error of purine metabolism associated with uric acid overproduction and a continuum spectrum of neurological manifestations depending on the degree of the enzymatic deficiency. The prevalence is estimated at 1/380,000 live births in Canada, and 1/235,000 live births in Spain. Uric acid overproduction is present inall HPRT-deficient patients and is associated with lithiasis and gout. Neurological manifestations include severe action dystonia, choreoathetosis, ballismus, cognitive and attention deficit, and self-injurious behaviour. The most severe forms are known as Lesch-Nyhan syndrome (patients are normal at birth and diagnosis can be accomplished when psychomotor delay becomes apparent). Partial HPRT-deficient patients present these symptoms with a different intensity, and in the least severe forms symptoms may be unapparent. Megaloblastic anaemia is also associated with the disease. Inheritance of HPRT deficiency is X-linked recessive, thus males are generally affected and heterozygous female are carriers (usually asymptomatic). Human HPRT is encoded by a single structural gene on the long arm of the X chromosome at Xq26. To date, more than 300 disease-associated mutations in the HPRT1 gene have been identified. The diagnosis is based on clinical and biochemical findings (hyperuricemia and hyperuricosuria associated with psychomotor delay), and enzymatic (HPRT activity determination in haemolysate, intact erythrocytes or fibroblasts) and molecular tests. Molecular diagnosis allows faster and more accurate carrier and prenatal diagnosis. Prenatal diagnosis can be performed with amniotic cells obtained by amniocentesis at about 15-18 weeks' gestation, or chorionic villus cells obtained at about 10-12 weeks' gestation. Uric acid overproduction can be managed by allopurinol treatment. Doses must be carefully adjusted to avoid xanthine lithiasis. The lack of precise understanding of the neurological dysfunction has precluded development of useful therapies. Spasticity, when present, and dystonia can be managed with benzodiazepines and gamma-aminobutyric acid inhibitors such as baclofen. Physical rehabilitation, including management of dysarthria and dysphagia, special devices to enable hand control, appropriate walking aids, and a programme of posture management to prevent deformities are recommended. Self-injurious behaviour must be managed by a combination of physical restraints, behavioural and pharmaceutical treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A familial disorder of uric acid metabolism and central nervous system function
Lesch, M., & Nyhan, W. L. (1964) · The American Journal of Medicine · doi:10.1016/0002-9343(64)90104-4 · Cited by 1,448
Seegmiller, J. E., Rosenbloom, F. M., & Kelley, W. N. (1967) · Science · doi:10.1126/science.155.3770.1682 · Cited by 1,220
A specific enzyme defect in gout associated with overproduction of uric acid.
Kelley, W. N., Rosenbloom, F. M., Henderson, J. F., & Seegmiller, J. E. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.57.6.1735 · Cited by 475
Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency in Gout
KELLEY, W. N., GREENE, M. L., ROSENBLOOM, F. M., HENDERSON, J. F., & SEEGMILLER, J. E. (1969) · Annals of Internal Medicine · doi:10.7326/0003-4819-70-1-155 · Cited by 446
Biochemical Evidence of Dysfunction of Brain Neurotransmitters in the Lesch-Nyhan Syndrome
Lloyd, K. G., Hornykiewicz, O., Davidson, L., Shannak, K., Farley, I., Goldstein, M., Shibuya, M., Kelley, W. N., & Fox, I. H. (1981) · New England Journal of Medicine · doi:10.1056/nejm198111053051902 · Cited by 373
Automated DNA sequencing of the human HPRT locus
Edwards, A., Voss, H., Rice, P., Civitello, A., Stegemann, J., Schwager, C., Zimmermann, J., Erfle, H., Caskey, C. T., & Ansorge, W. (1990) · Genomics · doi:10.1016/0888-7543(90)90493-e · Cited by 356
Gibbs, R. A., Nguyen, P.-N., Edwards, A., Civitello, A. B., & Caskey, C. T. (1990) · Genomics · doi:10.1016/0888-7543(90)90545-6 · Cited by 325
Jolly, D. J., Okayama, H., Berg, P., Esty, A. C., Filpula, D., Bohlen, P., Johnson, G. G., Shively, J. E., Hunkapillar, T., & Friedmann, T. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.2.477 · Cited by 324
Hyperuricemia and Gout: Classification, Complications and Management
Boss, G. R., & Seegmiller, J. E. (1979) · New England Journal of Medicine · doi:10.1056/nejm197906283002604 · Cited by 281
Delineation of the motor disorder of Lesch–Nyhan disease
Jinnah, H. A., Visser, J. E., Harris, J. C., Verdu, A., Larovere, L., Ceballos-Picot, I., Gonzalez-Alegre, P., Neychev, V., Torres, R. J., Dulac, O., et al. (2006) · Brain · doi:10.1093/brain/awl056 · Cited by 272
Self-citation
Cited by
Richette, P., & Bardin, T. (2010) · The Lancet · doi:10.1016/s0140-6736(09)60883-7 · Cited by 915
Gout: An old disease in new perspective – A review
Ragab, G., Elshahaly, M., & Bardin, T. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.008 · Cited by 599
Matsuo, H., Takada, T., Ichida, K., Nakamura, T., Nakayama, A., Ikebuchi, Y., Ito, K., Kusanagi, Y., Chiba, T., Tadokoro, S., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000237 · Cited by 437
Metadata
- Authors
- Torres, R. J., & Puig, J. G.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2007-12
- Volume
- 2
- Issue
- 1
- Pages
- 48-48
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W2108607187
- Cited by
- 307
- References
- 43
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. https://app.cochat.ai/papers/10.1186/1750-1172-2-48
- The paper
- Torres, R. J., & Puig, J. G. (2007). Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-2-48
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.